Home Visit
Upload
.png)
Her-2/Neu(C-Er-B2)(ERBB2) , FISH
50+ booked in last 3 days
No special precautions
Recommended for
Male, Female
Report
Within 1 Week
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
Overview
The detection of Her-2/Neu (C-Er-B2) status by fluorescence in situ hybridization (FISH) is a critical aspect in the diagnosis and treatment planning of certain cancers, most notably breast cancer. Her-2/neu is a proto-oncogene that encodes a receptor tyrosine kinase protein, and its overexpression or amplification is linked to aggressive tumor behavior and resistance to conventional therapies. Fluorescence in situ hybridization, or FISH, is a molecular diagnostic technique that allows for the visualization and quantification of specific DNA sequences, in this case, the ERBB2 gene, on a cellular level. By assessing Her-2/Neu status through FISH, clinicians gain valuable information about the cancer's molecular profile, aiding in the selection of targeted therapies such as Herceptin. This personalized approach enhances treatment efficacy and improves patient outcomes, exemplifying the pivotal role of Her-2/Neu (C-Er-B2) status determination by FISH in the management of certain malignancies.
Her-2/Neu(C-Er-B2)(ERBB2) , FISH Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the Her-2/Neu(C-Er-B2)(ERBB2) , FISH with a clear pricing structure.
The Her-2/Neu(C-Er-B2)(ERBB2) , FISH Price in Byculla is ₹ 11,870 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test measures the presence and quantity of the Her-2/Neu protein in breast and gastric cancer cells. Overexpression of this protein indicates an aggressive form of cancer, helping doctors determine the appropriate treatment plan for patients.
- To select patients with breast or gastric cancer for HER2-directed therapy
- To evaluate the effectiveness of HER2-targeted treatment
- To provide important information for personalised cancer management
- To assess the prognosis and potential aggressiveness of breast and gastric cancers
This test is recommended for patients with breast or gastric cancer. Doctors may suggest this test for patients who:
- Have a confirmed diagnosis of breast or gastric cancer
- May be eligible for HER2-directed therapy
- Require further evaluation to determine their treatment plan
A normal result indicates that the Her-2/Neu protein is not overexpressed, while an abnormal result suggests its overexpression. Abnormal results may indicate an aggressive form of breast or gastric cancer, but further evaluation is necessary. Discuss your results with your doctor for an accurate interpretation.
During this test:
- A small sample of tumor-containing tissue is collected.
- The sample is fixed in formalin and paraffin-embedded.
- The tissue is then analysed using a technique called FISH to detect and quantify the presence of the Her-2/Neu protein.
To prepare for this test:
- Provide your clinical history and histopathology/immunohistochemistry report.
- Ship the formalin-fixed paraffin-embedded (FFPE) tumour block at ambient temperature.
- Follow any additional instructions provided by your healthcare provider and the laboratory.
Additional tests that may be ordered alongside Her-2/Neu(C-Er-B2)(ERBB2) by FISH include:
- Hormone receptor testing: Determines if the cancer cells have receptors for estrogen or progesterone
- Ki-67 testing: Measures the growth rate of cancer cells
- EGFR mutation analysis: Detects specific mutations in the EGFR gene
HER2 fluorescence in situ hybridisation or HER2-FISH
Breast cancer is a type of cancer that originates in the breast tissue, while gastric cancer refers to cancer that develops in the stomach lining. Early detection and treatment significantly improve outcomes for both types of cancer.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp